AAAAAA

   
Results: 1-18 |
Results: 18
RIBOZYMES AS THERAPEUTIC AGENTS - ARE WE GETTING CLOSER
Authors: SCANLON KJ KASHANISABET M
Citation: Kj. Scanlon et M. Kashanisabet, RIBOZYMES AS THERAPEUTIC AGENTS - ARE WE GETTING CLOSER, Journal of the National Cancer Institute, 90(8), 1998, pp. 558-559
ADENOVIRAL MEDIATED ANTI-H-RAS RIBOZYME FOR THE TREATMENT OF BLADDER-CANCER
Authors: IRIE A ENGEBRAATEN O ANDEREGG B FLORL A HALKSMILLER M SCANLON KJ KASHANISABET M
Citation: A. Irie et al., ADENOVIRAL MEDIATED ANTI-H-RAS RIBOZYME FOR THE TREATMENT OF BLADDER-CANCER, The Journal of urology, 159(5), 1998, pp. 1106-1106
TOPICAL CORTICOSTEROIDS FOR MYCOSIS-FUNGOIDES - EXPERIENCE IN 79 PATIENTS
Authors: ZACKHEIM HS KASHANISABET M AMIN S
Citation: Hs. Zackheim et al., TOPICAL CORTICOSTEROIDS FOR MYCOSIS-FUNGOIDES - EXPERIENCE IN 79 PATIENTS, Archives of dermatology, 134(8), 1998, pp. 949-954
PREDICTION OF SENTINEL LYMPH-NODE MICROMETASTASIS BY HISTOLOGICAL FEATURES IN PRIMARY CUTANEOUS MALIGNANT-MELANOMA
Authors: MRAZGERNHARD S SAGEBIEL RW KASHANISABET M MILLER JR LEONG SPL
Citation: S. Mrazgernhard et al., PREDICTION OF SENTINEL LYMPH-NODE MICROMETASTASIS BY HISTOLOGICAL FEATURES IN PRIMARY CUTANEOUS MALIGNANT-MELANOMA, Archives of dermatology, 134(8), 1998, pp. 983-987
RESPONSE RATES IN PHOTOPHERESIS THERAPY FOR CUTANEOUS T-CELL LYMPHOMA
Authors: ZACKHEIM HS KASHANISABET M
Citation: Hs. Zackheim et M. Kashanisabet, RESPONSE RATES IN PHOTOPHERESIS THERAPY FOR CUTANEOUS T-CELL LYMPHOMA, Journal of the American Academy of Dermatology, 37(2), 1997, pp. 287-288
OPTIMAL SELECTIVE SENTINEL LYMPH-NODE DISSECTION IN PRIMARY MALIGNANT-MELANOMA
Authors: LEONG SPL STEINMETZ I HABIB FA MCMILLAN A GANS JZ ALLEN RE MORITA ET ELKADI M EPSTEIN HD KASHANISABET M SAGEBIEL RW
Citation: Spl. Leong et al., OPTIMAL SELECTIVE SENTINEL LYMPH-NODE DISSECTION IN PRIMARY MALIGNANT-MELANOMA, Archives of surgery, 132(6), 1997, pp. 666-673
ONCOGENE EXPRESSION IN MULTIDRUG-RESISTANT OVARIAN CARCINOMAS
Authors: JIAO L XIA L HORNG M KASHFIAN BI KASHANISABET M SCANLON KJ
Citation: L. Jiao et al., ONCOGENE EXPRESSION IN MULTIDRUG-RESISTANT OVARIAN CARCINOMAS, Onkologie, 19, 1996, pp. 19-22
TISSUE-SPECIFIC EXPRESSION OF AN ANTI-RAS RIBOZYME INHIBITS PROLIFERATION OF HUMAN-MALIGNANT MELANOMA-CELLS
Authors: OHTA Y KIJIMA H OHKAWA T KASHANISABET M SCANLON KJ
Citation: Y. Ohta et al., TISSUE-SPECIFIC EXPRESSION OF AN ANTI-RAS RIBOZYME INHIBITS PROLIFERATION OF HUMAN-MALIGNANT MELANOMA-CELLS, Nucleic acids research, 24(5), 1996, pp. 938-942
LOW-DOSE METHOTREXATE TO TREAT ERYTHRODERMIC CUTANEOUS T-CELL LYMPHOMA - RESULTS IN 29 PATIENTS
Authors: ZACKHEIM HS KASHANISABET M HWANG ST
Citation: Hs. Zackheim et al., LOW-DOSE METHOTREXATE TO TREAT ERYTHRODERMIC CUTANEOUS T-CELL LYMPHOMA - RESULTS IN 29 PATIENTS, Journal of the American Academy of Dermatology, 34(4), 1996, pp. 626-631
SUPPRESSION OF ME MALIGNANT PHENOTYPE OF MELANOMA-CELLS BY ANTIONCOGENE RIBOZYMES
Authors: OHTA Y KASHANISABET M SCANLON KJ
Citation: Y. Ohta et al., SUPPRESSION OF ME MALIGNANT PHENOTYPE OF MELANOMA-CELLS BY ANTIONCOGENE RIBOZYMES, Journal of investigative dermatology, 106(4), 1996, pp. 572-572
SUPPRESSION OF THE MALIGNANT PHENOTYPE OF MELANOMA-CELLS BY ANTIONCOGENE RIBOZYMES
Authors: OHTA Y KIJIMA H KASHANISABET M SCANLON KJ
Citation: Y. Ohta et al., SUPPRESSION OF THE MALIGNANT PHENOTYPE OF MELANOMA-CELLS BY ANTIONCOGENE RIBOZYMES, Journal of investigative dermatology, 106(2), 1996, pp. 275-280
APPLICATION OF RIBOZYMES TO CANCER GENE-THERAPY
Authors: KASHANISABET M SCANLON KJ
Citation: M. Kashanisabet et Kj. Scanlon, APPLICATION OF RIBOZYMES TO CANCER GENE-THERAPY, Cancer gene therapy, 2(3), 1995, pp. 213-223
OLIGONUCLEOTIDE-MEDIATED MODULATION OF MAMMALIAN GENE-EXPRESSION
Authors: SCANLON KJ OHTA Y ISHIDA H KIJIMA H OHKAWA T KAMINSKI A TSAI J HORNG G KASHANISABET M
Citation: Kj. Scanlon et al., OLIGONUCLEOTIDE-MEDIATED MODULATION OF MAMMALIAN GENE-EXPRESSION, The FASEB journal, 9(13), 1995, pp. 1288-1296
THERAPEUTIC APPLICATIONS OF RIBOZYMES
Authors: KIJIMA H ISHIDA H OHKAWA T KASHANISABET M SCANLON KJ
Citation: H. Kijima et al., THERAPEUTIC APPLICATIONS OF RIBOZYMES, Pharmacology & therapeutics, 68(2), 1995, pp. 247-267
REVERSAL OF THE IN-VIVO METASTATIC PHENOTYPE OF HUMAN OSTEOSARCOMA CELLS BY AN ANTI-CAPL (MTS-1) RIBOZYME (VOL 55, PG 77, 1995)
Authors: MAELANDSMO GM SKREDE M FLORENES VA KASHANISABET M HOVIG E GRIGORIAN MS HOVIG T MYKLEBOST O LUKANIDIN E SCANLON K FODSTAD O
Citation: Gm. Maelandsmo et al., REVERSAL OF THE IN-VIVO METASTATIC PHENOTYPE OF HUMAN OSTEOSARCOMA CELLS BY AN ANTI-CAPL (MTS-1) RIBOZYME (VOL 55, PG 77, 1995), Cancer research, 55(11), 1995, pp. 2484-2484
RIBOZYME-MEDIATED REVERSAL OF THE MULTIDRUG-RESISTANT PHENOTYPE
Authors: SCANLON KJ ISHIDA H KASHANISABET M
Citation: Kj. Scanlon et al., RIBOZYME-MEDIATED REVERSAL OF THE MULTIDRUG-RESISTANT PHENOTYPE, Proceedings of the National Academy of Sciences of the United Statesof America, 91(23), 1994, pp. 11123-11127
SUPPRESSION OF THE NEOPLASTIC PHENOTYPE IN-VIVO BY AN ANTI-RAS RIBOZYME
Authors: KASHANISABET M FUNATO T FLORENES VA FODSTAD O SCANLON KJ
Citation: M. Kashanisabet et al., SUPPRESSION OF THE NEOPLASTIC PHENOTYPE IN-VIVO BY AN ANTI-RAS RIBOZYME, Cancer research, 54(4), 1994, pp. 900-902
SUPPRESSION OF H-RAS-MEDIATED TRANSFORMATION IN NIH3T3 CELLS BY A RASRIBOZYME
Authors: FUNATO T SHITARA T TONE T JIAO L KASHANISABET M SCANLON KJ
Citation: T. Funato et al., SUPPRESSION OF H-RAS-MEDIATED TRANSFORMATION IN NIH3T3 CELLS BY A RASRIBOZYME, Biochemical pharmacology, 48(7), 1994, pp. 1471-1475
Risultati: 1-18 |